Advertisement
Research Article Free access | 10.1172/JCI113688
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Leppert, M. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Breslow, J. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Wu, L. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Hasstedt, S. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by O'Connell, P. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Lathrop, M. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Williams, R. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by White, R. in: JCI | PubMed | Google Scholar
Howard Hughes Medical Institute, University of Utah Medical Center, Salt Lake City 84132.
Find articles by Lalouel, J. in: JCI | PubMed | Google Scholar
Published September 1, 1988 - More info
Heterozygous hypobetalipoproteinemia is characterized by reduced plasma concentrations of LDL cholesterol, total triglycerides, and apo B to less than 50% of normal values. The molecular basis of this disorder remains unknown. The phenotype cosegregates with a DNA haplotype of the apo B gene in an Idaho pedigree, with a maximum decimal logarithm of the ratio (LOD) score of 7.56 at a recombination rate of zero. Individuals carrying this haplotype had total cholesterol levels of 96 mg/dl, LDL cholesterol levels of 37 mg/dl, triglycerides levels of 51 mg/dl, and apo B levels of 38 mg/dl. This study strongly suggests that apo B mutations underlie hypobetalipoproteinemia, and demonstrates the power of the candidate gene approach in linkage analysis for unraveling genetic determinants in metabolic disorders of undefined etiology.